Epic Test Fail Behind $4 Billion Rout Doesn't Faze Drugmaker
- SanBio co-founder Mori says SB623 still has ‘huge potential’
- Options remain for treating chronic stroke, brain injuries
This article is for subscribers only.
When Keita Mori, co-founder of SanBio Co., heard the news in January that the company’s flagship drug candidate had failed a major test, he almost lost his cool.
“It was a huge shock,” Mori said in an interview at the drugmaker’s Tokyo headquarters. “My head was spinning."